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Using data from the population-based Prescription Database of North Jutland County and the Danish Cancer Registry, we compared
cancer incidence among 29470 individuals prescribed low-dose aspirin at maximum doses of 150mg with expected incidence based
on county-specific cancer rates, during a 9-year study period. We observed 2381 cancer cases compared with 2187 expected,
yielding a standardised incidence ratio (SIR) of 1.09 (95% confidence interval (CI), 1.05–1.13). No apparent risk reductions were
found for cancers of the colon (SIR, 0.9; 95% CI, 0.7–1.1) or rectum (SIR, 1.0; 95% CI, 0.8–1.2), or for other site-specific cancers.
Increased SIRs were observed for kidney cancer (SIR, 1.4; 95% CI, 1.1–1.7) and brain cancer (SIR, 1.7; 95% CI, 1.3–2.2), although the
excess in the latter was confined to the first year of follow-up. Stratification by number of prescriptions and duration of follow-up
revealed no apparent trends. The SIR for colorectal cancer was close to unity (SIR, 0.9; 95% CI, 0.6–1.2) among persons with 10 or
more prescriptions who were followed for at least 5 years. Our results do not support a major protective effect of low-dose aspirin
on the development of colorectal or other cancers. The observed excesses of kidney and brain cancers are not likely to be causally
related to the use of low-dose aspirin.
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Epidemiologic and experimental evidence strongly suggests that
use of aspirin and other nonsteroidal anti-inflammatory drugs
(NSAIDs) reduces the risk for colorectal cancer (Thun et al, 2002).
A recent epidemiologic review (Garcia-Rodriguez and Huerta-
Alvarez, 2001) reported pooled relative risk estimates for colorectal
cancer of 0.71 (95% CI, 0.65–0.76) for use of aspirin and 0.63 (95%
CI, 0.57–0.70) for use of nonaspirin NSAIDs. The extent to which
aspirin and other NSAIDs protect against cancers other than
colorectal cancer has not been established. There is some
epidemiologic evidence that use of aspirin and other NSAIDs
reduces the risk for cancers of the stomach and oesophagus (Thun
et al, 1993; Farrow et al, 1998; Coogan et al, 2000), whereas the
results are conflicting for nongastrointestinal cancers, including
cancers of the lung (Thun et al, 1993; Schreinemachers and
Everson, 1994; Langman et al, 2000), breast (Khuder and Mutgi,
2001; Cotterchio et al, 2001; Meier et al, 2002), prostate (Norrish
et al, 1998; Langman et al, 2000; Leitzmann et al, 2002), bladder
(Castelao et al, 2000; Langman et al, 2000), and ovary (Akhmed-
khanov et al, 2001; Meier et al, 2002).
Only limited data are available on what dose and duration of
treatment with aspirin and other NSAIDs are necessary to reduce
the risks for colorectal and, potentially, other cancers. Some
studies have evaluated the association between regular use of low-
dose aspirin and colorectal cancer risk (Giovannucci et al, 1995;
Rosenberg et al, 1998; Stu ¨rmer et al, 1998; Garcia-Rodriguez and
Huerta-Alvarez, 2001), but the results are conflicting and little
information has been provided for other cancer sites. Any
substantial cancer-preventive effect of low-dose aspirin would
have important public health implications. We have therefore
examined the incidence of colorectal and other cancers in a Danish
population-based cohort of persons receiving prescriptions for
low-dose aspirin.
MATERIAL AND METHODS
The study was conducted within the population of North Jutland, a
county with nearly 500000 inhabitants, representing approxi-
mately 9% of the total Danish population. Through a computerised
accounting system maintained by Danish pharmacies, the tax-
supported health insurance programme in Denmark refunds part
of the costs of most drugs, including some over-the-counter
medications, if prescribed by physicians. In North Jutland, this
accounting system also provides prescription data to the
Pharmacoepidemiologic Prescription Database (Gaist et al, 1997),
initiated in 1989, which retains key data on prescriptions for
refundable drugs dispensed from all pharmacies in the county. The
data includes the type of drug prescribed according to the
Anatomical Therapeutical Chemical (ATC) classification system
(Capella ´, 1993), tablet size, date of prescription, and the patient’s
civil registry number (a unique number assigned to all Danish
Received 26 September 2002; revised 15 November 2002; accepted 15
November 2002
*Correspondence: Dr S Friis; E-mail: friis@cancer.dk
British Journal of Cancer (2003) 88, 684–688
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yresidents that encodes gender and date of birth). The use of the
civil registry number ensures that complete individual prescription
histories can be established, and permits valid linkage of
information between registers.
Through the Prescription Database, we identified 32794
individuals prescribed low-dose aspirin between 1 January 1989
and 31 December 1995. These prescriptions were identified by the
ATC codes for aspirin (B01AC06 and N02BA01) in tablet sizes of
75, 100 or 150mg. All preparations of aspirin are available over-
the-counter in Denmark, but low-dose aspirin, which is used
almost exclusively for secondary prevention of cardiovascular
disease, is generally prescribed by physicians, being reimbursable
by 50% through the national health insurance programme. In
Denmark, the recommended dose of low-dose aspirin for
secondary prevention of cardiovascular disease is 75–150mg once
daily, and the preparation is mainly prescribed in packets for 3-
month use (Srensen et al, 2000).
Overall, 668 (2.0%) of the identified persons prescribed low-dose
aspirin were excluded because of (i) residency outside the county
of North Jutland at the date of prescription (n¼617); (ii) an
invalid civil registry number (n¼15); (iii) death prior to or at the
date of prescription (n¼19); or (iv) parent (of patient) registered
as customer (n¼17). After these exclusions, 32126 (98.0%)
persons were left for subsequent record linkage.
Information on cancer occurrence was obtained by linkage
to the Danish Cancer Registry, which has recorded incident
cases of cancer on a nationwide basis since 1943 (Storm et al,
1997). Cancers were classified according to a modified
Danish version of the International Classification of Diseases, 7th
revision (Storm et al, 1997). Study subjects with a cancer diagnosis,
except nonmelanoma skin cancer, prior to the date of first
recorded prescription for low-dose aspirin (n¼2656; 8.1%) were
excluded, leaving a final study cohort of 29470 (89.9%)
individuals.
The observation period for cancer began on the date of the first
recorded prescription for low-dose aspirin and ended on the date
of first primary cancer diagnosis except nonmelanoma skin cancer
(n¼1962), date of death (n¼8493), or 31 December 1997
(n¼19015), whichever occurred first. Information on date of
death was obtained through linkage to the National Mortality Files
(Juel and Helweg-Larsen, 1999). The observed number of cancer
cases among the cohort members was compared with the number
expected based on cancer incidence rates among the general
population of North Jutland. To obtain expected numbers, county-
specific incidence rates of first primary cancers, calculated by sex,
5-year age groups, and 5-year calendar periods, were applied to the
corresponding person-years of the cohort members. The standar-
dised incidence ratio (SIR), that is, the ratio of the observed to the
expected number of cancer cases, and 95% confidence intervals
(CIs) were calculated for total cancer and for specific sites based on
the assumption that the observed cancer cases followed a Poisson
distribution (Bailar and Ederer, 1964). We also computed SIRs
stratified by the number of low-dose aspirin prescriptions and by
years of follow-up. For these analyses, each study subject
contributed person-years to one to four categories of prescription
frequency (1; 2–4; 5–9; or X10 prescriptions), with follow-up for
cancer (o1; 1–4; 5–9 years) beginning on the date of the first
prescription within the given category of prescription frequency. A
test for linear trend was used to evaluate trends in SIRs with the
number of low-dose aspirin prescriptions or years of follow-up.
RESULTS
Characteristics of the study cohort of 15058 men (51%) and 14412
women (49%) are presented in Table 1. The mean age at cohort
entry, that is, time of first recorded prescription for low-dose
aspirin, was 70 years, with only 6% of the cohort being younger
than 50 years at entry. The cohort members accrued a total of
121562 person-years, with an average length of follow-up since the
first recorded prescription for low-dose aspirin of 4.1 years (range,
0–9 years); 80% of subjects received two or more prescriptions for
low-dose aspirin, and 32% received 10 or more prescriptions.
Overall, we observed 2381 cancer cases compared with 2187
expected, yielding a SIR of 1.09 (95% CI, 1.05–1.13) (Table 2). No
apparent risk reductions were observed for cancers of the
gastrointestinal tract, including cancers of the colon (SIR, 0.9;
95% CI, 0.7–1.1), rectum (SIR, 1.0; 95% CI, 0.8–1.2), and stomach
(SIR, 1.1; 95% CI, 0.8–1.3). Increased SIRs were found for cancers
of the kidney (SIR, 1.4; 95% CI, 1.1–1.7) and brain (SIR, 1.7; 95%
CI, 1.3–2.2). Slight risk elevations were seen for several smoking-
related cancers, including cancers of the buccal cavity and pharynx
(SIR, 1.3; 95% CI, 0.9–1.7), urinary bladder (SIR, 1.2; 95% CI, 1.0–
1.4), oesophagus (SIR, 1.3; 95% CI, 0.9–1.9), larynx (SIR, 1.5; 95%
CI, 0.9–2.4), and leukaemia (SIR, 1.3; 95% CI, 1.0–1.6), whereas
the SIR for lung cancer was close to expectation (SIR, 1.1; 95% CI,
0.9–1.2). The SIR estimates for site-specific cancers were similar in
men and women, except for cancer of the kidney (SIR, 1.6 (95% CI,
1.1–2.1) in men vs 1.1 (95% CI, 0.7–1.6) in women) and non-
Hodgkin’s lymphoma (SIR, 1.4 (95% CI, 1.0–1.9) in men vs 0.9
(95% CI, 0.5–1.4) in women).
The SIRs did not vary markedly when stratified by age. The SIR
for total cancer was 1.14 (95% CI, 1.07–1.22) among persons below
70 years at cohort entry and 1.06 (95% CI, 1.01–1.11) among older
persons (data not shown). Similarly, for specific cancer sites,
including colorectal cancer and kidney cancer, the SIR estimates
did not differ substantially between these two age groups.
Table 3 presents SIR estimates, stratified by number of
prescriptions for low-dose aspirin and years of follow-up, for total
cancer, selected gastrointestinal cancers, and kidney cancer.
Overall, stratification by duration of follow-up yielded SIRs for
total cancer of 1.2 (95% CI, 1.1–1.3) for less than 1 year of follow-
up, 1.1 (95% CI, 1.0–1.1) for 1–4 years of follow-up, and 1.1 (95%
CI, 1.0–1.2) for 5–9 years of follow-up. Similar SIRs were observed
for total cancer in the four categories of prescription frequency.
The SIRs for colorectal and stomach cancer decreased slightly with
Table 1 Characteristics of users of low-dose aspirin recorded in the
Prescription Database of North Jutland County, Denmark, between 1989
and 1995
Characteristic No. (%)
Total no. of patients 29470 100
Men 15058 51
Women 14412 49
Age at entry
a (years)
o50 1751 6
50–69 11456 39
X70 16263 55
Mean age at entry
a 70 years
Year of entry
a
1989–1991 11044 37
1992–1993 9000 31
1994–1995 9426 32
Number of prescriptions
1 5794 20
2–4 7069 24
5–9 7091 24
X10 9516 32
aDate of first recorded prescription for low-dose aspirin.
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follow-up, but none of the trends was statistically significant. No
consistent trends in risk estimates were observed for cancers of the
oesophagus or kidney. Among persons with 10 or more prescrip-
tions, the SIR for kidney cancer was of the same magnitude in the
1- to 4-year (SIR, 1.6; 95% CI, 0.7–3.1) and 5- to 9-year (SIR, 1.7;
95% CI, 0.9–2.9) follow-up periods.
The overall increased SIR for brain cancer was entirely due to an
excess in the first year of follow-up (SIR, 4.7; 95% CI, 3.4–6.3)
among persons receiving one prescription (SIR, 6.2; 95% CI, 4.1–
9.1) or 2–4 prescriptions (SIR, 3.5; 95% CI, 2.0–5.7) (data not
shown). For the remaining sites of interest, including cancers of
the lung, breast, prostate, bladder, and ovary, stratification by
number of prescriptions and years of follow-up revealed no
consistent trends (data not shown).
DISCUSSION
In this population-based cohort study, we found little evidence of a
reduced risk for colorectal or other cancers among nearly 30000
individuals receiving prescriptions for low-dose aspirin. There was
a slight decreasing trend in risks for colorectal and stomach
cancers with increasing number of prescriptions and length of
follow-up, however, the SIRs for both cancers were close to unity
among persons with 10 or more prescriptions (equivalent to an
estimated period of aspirin therapy of minimum 30 months) who
were followed for at least 5 years.
Our results are consistent with those of two previous studies
reporting on colorectal cancer risk among users of low-dose
aspirin. In the only randomised clinical trial of aspirin and cancer
risk published to date (Stu ¨rmer et al, 1998), based on the
Physicians’ Health Study in the United States, both randomised
(5 years of follow-up) and post-trial observational analyses (up to
12 years of follow-up) revealed no association between the
assigned low dose of aspirin (325mg every other day) and risk
for colorectal cancer. Limitations however, include possible
exposure misclassification in the post-trial analysis (exposure
was assessed only at the beginning of the observational follow-up
period) and limited statistical power. A large nested case – control
study (Garcia-Rodriguez and Huerta-Alvarez, 2001), based on the
General Practice Research Database in the UK, reported a
significant reduction in risk for colorectal cancer (OR, 0.6; 95%
CI, 0.4–0.9) associated with the current use of aspirin at daily
doses of 300mg or greater for at least 6 months, whereas daily
doses of 75 and 150mg aspirin were not associated with a reduced
risk. A limitation of that study was the relatively small number of
subjects with long continuous (42 years) exposure to aspirin. In
contrast, a population-based case – control study (Rosenberg et al,
1998) and a cohort analysis based on the Nurses’ Health Study
(Giovannucci et al, 1995) reported that regular users of low-dose
aspirin had a substantially reduced risk for colorectal cancer.
However, the doses examined in the latter study had upper limits
intermediate between cardioprotective and anti-inflammatory
doses, and no results were presented separately for low-dose
aspirin as defined in the present study.
The strengths of our study are the population-based design, the
continuously updated data on aspirin use based on a prescription
database covering all pharmacies in a Danish county, the relatively
large number of outcomes, and the complete follow-up obtained
by use of the unique civil registry number and computerised
linkage to the Danish Cancer Registry. The Cancer Registry covers
the entire population of Denmark and has been shown to have
accurate and virtually complete ascertainment of cancer cases
(Storm et al, 1997). Although low-dose aspirin is available over the
counter, a 50% government refund at the time of prescription
exists and is used predominantly for conditions requiring
physician attendance; thus, we have probably identified most of
the patients using low-dose aspirin on a regular basis in the North
Jutland population during the period of registration.
Table 2 Standardised incidence ratios (SIR) and 95% confidence intervals (CI) for cancers at selected sites, stratified by sex,
a among users of low-dose
aspirin in North Jutland county, Denmark, 1989–1997
Men Women Total
Site of cancer (modified ICD-7 code) Obs
b SIR 95% CI Obs
b SIR 95% CI Obs
b SIR 95% CI
All malignant neoplasms (140–205) 1362 1.10 1.04–1.16 1019 1.08 1.01–1.14 2381 1.09 1.05–1.13
Buccal cavity and Pharynx (140–148) 32 1.2 0.8–1.7 16 1.5 0.9–2.4 48 1.3 0.9–1.7
Digestive system (150–159) 303 1.0 0.9–1.1 247 1.0 0.9–1.2 550 1.0 0.9–1.1
Oesophagus (150) 17 1.3 0.7–2.0 9 1.5 0.7–2.8 26 1.3 0.9–1.9
Stomach (151) 50 1.1 0.8–1.5 18 0.9 0.5–1.3 68 1.1 0.8–1.3
Colon (153) 108 1.1 0.9–1.3 87 0.9 0.7–1.1 195 0.9 0.7–1.1
Rectum (154) 67 1.0 0.8–1.3 37 0.9 0.6–1.3 104 1.0 0.8–1.2
Liver (155) 16 1.1 0.6–1.7 5 0.7 0.2–1.7 21 1.0 0.6–1.5
Pancreas (157) 27 0.9 0.6–1.4 35 1.2 0.8–1.6 62 1.1 0.8–1.3
Larynx (161) 16 1.4 0.8–2.3 4 2.7 0.7–6.8 20 1.5 0.9–2.4
Lung (162) 173 1.0 0.8–1.1 101 1.3 1.0–1.5 274 1.1 0.9–1.2
Breast (170) 1 0.6 0.0–3.2 148 0.9 0.8–1.1 149 0.9 0.8–1.1
Female genital organs (171–176) FF F 108 1.1 0.9–1.3 108 1.1 0.9–1.3
Cervix uteri FF F 15 0.9 0.5–1.6 15 0.9 0.5–1.6
Corpus uteri FF F 45 1.1 0.8–1.5 45 1.1 0.8–1.5
Ovary FF F 34 1.1 0.7–1.5 34 1.1 0.7–1.5
Prostate (177) 196 1.1 1.0–1.3 FF F 196 1.1 1.0–1.3
Kidney (180) 45 1.6 1.1–2.1 22 1.1 0.7–1.6 67 1.4 1.1–1.7
Urinary bladder (181) 134 1.2 1.0–1.5 27 0.9 0.6–1.4 161 1.2 1.0–1.4
Melanoma (190) 31 1.3 0.9–1.8 21 1.1 0.7–1.7 52 1.2 0.9–1.6
Nonmelanoma skin cancer (191) 246 1.1 0.9–1.2 161 1.0 0.9–1.2 407 1.1 0.9–1.2
Brain (193) 33 1.5 1.0–2.1 37 1.9 1.4–2.7 70 1.7 1.3–2.2
Non-Hodgkin’s lymphoma (200, 202) 37 1.4 1.0–1.9 20 0.9 0.5–1.4 57 1.1 0.9–1.5
Leukaemia (204) 44 1.2 0.9–1.7 25 1.4 0.9–2.0 69 1.3 1.0–1.6
aPerson-years of observation in each stratum: men, 61093; women, 60469.
bObserved number of cases.
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data, with no information on indications, dose schedules, or degree
of compliance. However, a large proportion of our cohort
members can be assumed to have received low-dose aspirin for
secondary prevention of cardiovascular disease at daily doses of
75–150mg. Also, the fact that drug exposure was based on
prescriptions actually dispensed at pharmacies and paid for in part
by the patient implies high compliance. Nonetheless, some
misclassification because of noncompliance is possible, leading
to attenuation of the risk estimates.
Our study had a number of other limitations. We had no data on
over-the-counter purchase of high-dose aspirin. Use patterns of
high-dose aspirin and nonaspirin NSAIDs for analgesic or anti-
inflammatory purposes may have been different among
persons prescribed low-dose aspirin than among the general
population, thus introducing possible exposure misclassification
of aspirin and/or confounding by nonaspirin NSAIDs. The finding
of slightly increased SIRs for several smoking-related cancers
is consistent with the fact that smoking is a strong indepen-
dent risk factor for both ischaemic cardiovascular disease
and cancer (Dreyer and Olsen, 1998), and that low-dose aspirin
in Denmark is prescribed almost exclusively as secondary
prevention in patients with cardiovascular disease. Our inability
to adjust for concurrent NSAID use, smoking, and other potential
confounders may have obscured a cancer-preventive effect
of low-dose aspirin. Nevertheless, the absence of any substantial
trends in SIRs with the number of prescriptions of low-dose
aspirin or years of follow-up argues against any important
inverse association between use of low-dose aspirin and cancer
risk.
The increased risk for kidney cancer may partly reflect an
increased prevalence of hypertension among the study subjects
with ischaemic heart disease. Patients with kidney tumours may
present with hypertension some years prior to kidney cancer
diagnosis (Steffens et al, 1992), and there is increasing evidence
that hypertension per se increases the risk for kidney cancer
(McLaughlin and Lipworth, 2000). Other arguments against a
causal relation between the use of low-dose aspirin and kidney
cancer are the gender difference and the absence of a dose –
response relation or temporal trend in the risk estimates for kidney
cancer in this study, in addition to the largely null results from
previous epidemiological studies of aspirin intake and kidney
cancer (McLaughlin and Lipworth, 2000).
The increased risk observed for brain cancer is likely to be a
result of ‘reverse causation’ (i.e. prescription for low-dose aspirin
to treat symptoms of brain cancer). The excess risk was confined
exclusively to the first year of follow-up among patients who
received only a few prescriptions for low-dose aspirin. Some
patients with brain tumours may have received anti-thrombotic
treatment with low-dose aspirin prior to diagnosis, because they
presented with symptoms resembling thrombotic cerebral dis-
eases, for example, transient ischaemic attacks.
The duration of exposure to aspirin necessary to prevent
colorectal or other cancers has not been firmly established. In one
study, a protective effect at doses of at least 300mg daily became
evident after only 6 months of continuous treatment (Garcia-
Table 3 Standardised incidence ratios (SIR) and 95% confidence intervals (CI) for selected cancer sites among users of low-dose aspirin, stratified by
number of prescriptions and years of follow-up, North Jutland county, Denmark, 1989–1997
Follow-up (years)
Site of cancera and
o1 1–4 5–9 Total
No. of prescriptions (1,2–4, 5–9, X10) Obs SIR 95% CI Obs SIR 95% CI Obs SIR 95% CI Obs SIR 95% CI
All sites
1 277 1.3 1.1–1.4 189 1.1 0.9–1.2 59 1.2 0.9–1.5 525 1.2 1.1–1.3
2–4 265 1.1 0.9–1.2 323 1.2 1.0–1.3 60 1.1 0.8–1.4 648 1.1 1.0–1.2
5–9 26 1.3 0.8–1.8 450 1.0 0.9–1.1 71 1.0 0.8–1.2 547 1.0 0.9–1.1
X10 1 4.3 0.1–23.7 269 1.1 1.0–1.2 391 1.1 1.0–1.2 661 1.1 1.0–1.2
Total 569 1.2 1.1–1.3 1231 1.1 1.0–1.1 581 1.1 1.0–1.2 2381 1.1 1.0–1.1
Colorectal
1 27 0.9 0.6–1.3 31 1.3 0.9–1.8 10 1.5 0.7–2.7 68 1.1 0.9–1.4
2–4 39 1.1 0.8–1.6 48 1.3 0.9–1.7 3 0.4 0.1–1.2 90 1.1 0.9–1.4
5–9 3 1.1 0.2–3.1 54 0.9 0.6–1.1 8 0.8 0.3–1.6 65 0.9 0.7–1.1
X10 0 FF 33 0.9 0.7–1.4 43 0.9 0.6–1.2 76 0.9 0.7–1.1
Total 69 1.0 0.8–1.3 166 1.0 0.9–1.2 64 0.9 0.7–1.1 299 1.0 0.9–1.1
Stomach
1 8 1.2 0.5–2.3 10 1.9 0.9–3.6 1 0.7 0.0–4.0 19 1.4 0.9–2.2
2–4 6 0.8 0.3–1.7 10 1.2 0.6–2.2 2 1.3 0.1–4.6 18 1.0 0.6–1.6
5–9 0 FF 14 1.0 0.6–1.7 1 0.5 0.0–2.7 15 0.9 0.5–1.5
X10 0 FF 8 1.1 0.5–2.2 8 0.8 0.3–1.5 16 0.9 0.5–1.5
Total 14 0.9 0.5–1.6 42 1.2 0.9–1.6 12 0.8 0.4–1.4 68 1.1 0.8–1.3
Oesophagus
1 5 2.5 0.8–5.9 2 1.3 0.1–4.5 2 4.6 0.5–16.6 9 2.3 1.0–4.3
2–4 1 0.5 0.0–2.5 2 0.8 0.1–2.8 1 2.0 0.0–11.3 4 0.8 0.2–1.9
5–9 0 FF 3 0.7 0.1–2.1 2 3.1 0.3–11.1 5 1.0 0.3–2.4
X10 0 FF 4 1.8 0.4–4.6 4 1.2 0.3–3.2 8 1.5 0.6–2.9
Total 6 1.4 0.5–3.0 11 1.1 0.5–1.9 9 1.9 0.9–3.6 26 1.3 0.9–1.9
Kidney
1 7 1.4 0.5–2.8 4 1.0 0.3–2.5 3 2.7 0.5–7.9 14 1.4 0.7–2.3
2–4 10 1.7 0.8–3.2 2 0.3 0.0–1.1 2 1.7 0.2–6.0 14 1.1 0.6–1.8
5–9 0 FF 15 1.5 0.8–2.4 2 1.3 0.1–4.5 17 1.4 0.8–2.2
X10 0 FF 9 1.6 0.7–3.1 13 1.7 0.9–2.9 22 1.7 1.0–2.5
Total 17 1.5 0.9–2.4 30 1.1 0.8–1.6 20 1.7 1.1–2.7 67 1.4 1.1–1.7
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suggested that longer periods of treatment are necessary to achieve
a protective effect. Our observation period of up to 9 years with an
average follow-up of 4.1 years may be too short to detect a cancer-
preventive effect, even if the effect is on disease progression.
However, a substantial proportion of the patients were likely to be
prevalent users at the start of the registration period and therefore
to have had exposure before the observation period.
In summary, patients prescribed low-dose aspirin at doses of
maximum 150mg were not at a substantially reduced risk for
colorectal or other cancers. The available evidence so far does not
support a major protective effect of low-dose aspirin on the
development of colorectal or other cancers. Further studies are
needed to establish what dose and duration of treatment by aspirin
and other NSAIDs are necessary to prevent colorectal and possibly
other cancers.
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